Skip to main content

ESBL and AmpC Confirm Kit

Intended Use

Current susceptibility tests are not accurate enough for surveillance of ESBL and AmpC producing pathogens. Laboratories testing ESBL and AmpC, need to be aware, that some of these organisms may test false positive for ESBL, using CLSI methodology.

  • Simple to test
  • Easy to interpret
  • Long shelflife
  • After opening, room temperature storage (≤ 25°C)
  • High sensitivity and specificity

An Antimicrobial Resistance mechanism should be suspected if:

ESBL: I/R to one or both of cefotaxime and ceftazidime or R for cefpodoxime

AmpC: R to one or both of cefotaxime and ceftazidime and R for cefoxitin

ESBL will show:

  • Synergy with clavulanic acid

AmpC will show:

  • Synergy with cloxacillin
  • No synergy indicates other mechanisms such as porin loss

It is possible for isolates to carry and display both ESBL and AmpC resistance mechanism at the same time, this kit will identify this when it occurs.

EUCAST compliance (guidelines for the detection of resistance mechanisms):
...only the combination of cefotaxime and ceftazidime are used for confirmatory tests

Combined disc test
Apply one tablet of:
Cefotaxime + Cloxacillin (CTXCX)

Cefotaxime + Clavulanate (CTX+C)

Ceftazidime + Cloxacillin (CAZCX)

Ceftazidime + Clavulanate (CAX+C)

Cefotaxime + Cloxacillin + Clavulanate (CTXCC)

Ceftazidime + Cloxacillin + Clavulanate (CAZCC)
On an inoculated Mueller-Hinton agar plate (McFarland 0.5).

Specifications

  • Quantity: 50 tests
  • Product Code: 98019